Browse By: Country ι Category ι Tag
Home  »  Renal Cell Carcinoma

Renal Cell Carcinoma Market Research Reports

More

Axitinib (Renal Cell Carcinoma) Analysis and Forecasts to 2020
SummaryGlobalDatas pharmaceuticals report, Axitinib (Renal Cell Carcinoma)- Analysis and Forecasts to 2020 provides Axitinib sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2020). The report also includes information on Renal Cell Carcinoma market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.Note: This
Published Date: Oct 2011
Published By: GlobalData

Price: $2000
Dovitinib (Renal Cell Carcinoma) Analysis and Forecasts to 2020
SummaryGlobalDatas pharmaceuticals report, Dovitinib (Renal Cell Carcinoma)- Analysis and Forecasts to 2020 provides Dovitinib sales forecasts for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Renal Cell Carcinoma market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.Note: This is a
Published Date: Oct 2011
Published By: GlobalData

Price: $2000
Avastin (Renal Cell Carcinoma) Analysis and Forecasts to 2020
SummaryGlobalDatas pharmaceuticals report, Avastin (Renal Cell Carcinoma)- Analysis and Forecasts to 2020 provides Avastin sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2008-2020). The report also includes information on Renal Cell Carcinoma market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.Note: This i
Published Date: Oct 2011
Published By: GlobalData

Price: $2000
Rencarex (Renal Cell Carcinoma) Analysis and Forecasts to 2020
GlobalDatas pharmaceuticals report, Rencarex (Renal Cell Carcinoma)Analysis and Forecasts to 2020 provides Rencarex sales forecasts for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2015-2020). The report also includes information on Renal Cell Carcinoma market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. Note: This i
Published Date: Oct 2011
Published By: GlobalData

Price: $2000
Anyara (Renal Cell Carcinoma) Analysis and Forecasts to 2020
SummaryGlobalDatas pharmaceuticals report, Anyara (Renal Cell Carcinoma)- Analysis and Forecasts to 2020 provides Anyara sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Renal Cell Carcinoma market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.Note: This is
Published Date: Oct 2011
Published By: GlobalData

Price: $2000
Nexavar (Renal Cell Carcinoma) Analysis and Forecasts to 2020
SummaryGlobalDatas pharmaceuticals report, Nexavar (Renal Cell Carcinoma)- Analysis and Forecasts to 2020 provides Nexavar sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2006-2020). The report also includes information on Renal Cell Carcinoma market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.Note: This i
Published Date: Oct 2011
Published By: GlobalData

Price: $2000
Sutent (Renal Cell Carcinoma) Analysis and Forecasts to 2020
SummaryGlobalDatas pharmaceuticals report, Sutent (Renal Cell Carcinoma)- Analysis and Forecasts to 2020 provides Sutent sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2006-2020). The report also includes information on Renal Cell Carcinoma market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.Note: This is
Published Date: Oct 2011
Published By: GlobalData

Price: $2000
Torisel (Renal Cell Carcinoma) Analysis and Forecasts to 2020
SummaryGlobalDatas pharmaceuticals report, Torisel (Renal Cell Carcinoma)- Analysis and Forecasts to 2020 provides Torisel sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Renal Cell Carcinoma market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.Note: This i
Published Date: Oct 2011
Published By: GlobalData

Price: $2000
Afinitor (Renal Cell Carcinoma) Analysis and Forecasts to 2020
SummaryGlobalDatas pharmaceuticals report, Afinitor (Renal Cell Carcinoma) Analysis and Forecasts to 2020 provides Afinitor sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2009-2020). The report also includes information on Renal Cell Carcinoma market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.Note: This
Published Date: Oct 2011
Published By: GlobalData

Price: $2000
Tivozanib (Renal Cell Carcinoma) Analysis and Forecasts to 2020
SummaryGlobalDatas pharmaceuticals report, Tivozanib (Renal Cell Carcinoma) Analysis and Forecasts to 2020 provides Tivozanib sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Renal Cell Carcinoma market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.Note: Thi
Published Date: Oct 2011
Published By: GlobalData

Price: $2000
Votrient (Renal Cell Carcinoma) Analysis and Forecasts to 2020
GlobalDatas pharmaceuticals report, Votrient (Renal Cell Carcinoma) Analysis and Forecasts to 2020 provides Votrient sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2009-2020). The report also includes information on Renal Cell Carcinoma market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. Scope
Published Date: Oct 2011
Published By: GlobalData

Price: $2000

Back To Top